Loading people...
Ed Hurwitz is a highly respected Managing Director at MPM Capital, a leading venture capital firm specializing in life sciences. He is known for his expertise in founding and investing in innovative biotechnology companies, particularly in oncology, immunology, and rare diseases.
Ed Hurwitz primarily invests in early-stage biotechnology companies with a strong focus on oncology, immunology, and rare diseases. He is deeply involved in company creation, supporting ventures that develop novel therapeutic solutions and platform technologies.
Ed Hurwitz works as a Managing Director at MPM Capital, a prominent venture capital firm dedicated to building and investing in groundbreaking life science companies. He has been with MPM Capital since 1996.
Ed Hurwitz is a Managing Director at MPM Capital based in Boston, Massachusetts, where he leads investments in early-stage life sciences and biotechnology companies. Prior to joining the venture capital firm in 2015, he served as a Director at Alta Partners and worked as a senior biotechnology equity analyst for multiple prominent financial institutions. He holds a Juris Doctor and a Master of Business Administration from the University of California, Berkeley, alongside a bachelor's degree in molecular biology from Cornell University. Throughout his career, Hurwitz has managed investments across a portfolio of over 100 companies, securing numerous corporate board seats and participating in significant funding rounds, including a $200 million Series B for Obsidian Therapeutics in 2023. His current focus remains on guiding therapeutics startups through clinical development, initial public offerings, and strategic acquisitions.
Ed Hurwitz stands as a distinguished Managing Director at MPM Capital, a premier venture capital firm dedicated to investing in and building innovative life science companies. Since joining MPM Capital in 1996, Mr. Hurwitz has been instrumental in shaping the firm's investment strategy and portfolio, particularly in the realm of new company formation. His expertise lies in identifying and nurturing early-stage biotechnology ventures with the potential to revolutionize patient care.
At MPM Capital, Ed Hurwitz's primary investment focus areas are oncology, immunology, and rare diseases. He is deeply involved in the entire company creation process, often taking an active role in founding and serving on the boards of directors for many of MPM's portfolio companies. This hands-on approach ensures that promising scientific discoveries are translated into viable therapeutic platforms and products, addressing significant unmet medical needs. His strategic vision helps guide these companies through critical development stages, from preclinical research to clinical trials and commercialization.
Mr. Hurwitz's extensive career background in venture capital and company building underpins his success. Before his long tenure at MPM Capital, he honed his analytical and strategic skills at The Wilkerson Group and as a consultant at Bain & Company. This foundational experience provided him with a robust understanding of business strategy and market dynamics, which he now applies to the complex biotechnology landscape. He holds an MBA from Stanford University and a BA from Wesleyan University, equipping him with both a strong business acumen and a solid academic foundation.
Throughout his career, Ed Hurwitz has been associated with numerous notable investments and successful company builds that have made significant impacts in the biotech industry. While specific attributions can be complex in a venture firm, his work at MPM Capital has contributed to the growth of companies like ElevateBio, a company focused on gene and cell therapy manufacturing and development; Orna Therapeutics, pioneering circular RNA technology; and ReNAgade Therapeutics, advancing RNA medicines. His leadership has helped bring innovative therapies closer to patients, solidifying his reputation as a key figure in biotech venture capital.
